{"product_id":"coo-bcg-matrix","title":"(COO) The Cooper Companies, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis The Cooper Companies, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. What you see on this page is a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMiSight 1 day myopia-control lens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChildhood myopia is a fast-growing global market, with about 30% of people already affected and forecasts near 50% by 2050. MiSight 1 day is the first FDA-approved soft lens shown to slow myopia progression, giving CooperVision an early-mover edge. It still needs wider rollout and steady marketing, but the growth runway stays strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiofinity Toric contact lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiofinity Toric serves the large astigmatism market; astigmatism affects about 30% of people, so demand is broad and recurring. Biofinity is a core CooperVision brand with strong practitioner trust and global reach, which supports steady prescription flow. That mix of scale and growth keeps it in the Star quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiofinity Multifocal contact lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiofinity Multifocal sits in a premium niche, and rising presbyopia supports demand: the WHO has said 2.2 billion people had near vision impairment in 2025, with aging driving more cases. Cooper Companies can keep this a Star by funding awareness and fitter training, since premium multifocal lenses win on comfort and convenience. CooperVision’s scale and fitting support help defend share as more older adults seek daily-wear upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDaily disposable silicone hydrogel lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDaily disposable silicone hydrogel lenses are a Star in The Cooper Companies, Inc. BCG Matrix because the format is still one of the fastest-growing parts of the contact lens market. CooperVision’s clariti 1 day and MyDay sit right in that demand shift, and the category needs steady promotion, fitting help, and strong retailer shelf space to keep growing.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast-growing one-day lens format\u003c\/li\u003e\n\u003cli\u003eCooperVision has key brands here\u003c\/li\u003e\n\u003cli\u003eSupport and placement drive share\u003c\/li\u003e\n\u003cli\u003eFits a high-growth, high-share profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn fiscal 2025, The Cooper Companies, Inc. continued to lean on CooperVision as its core growth engine, and daily disposables stay central to that mix. The logic is simple: more first-time wearers want comfort and convenience, and silicone hydrogel one-day lenses answer both.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCooperSurgical fertility consumables and embryo services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperSurgical’s fertility consumables and embryo services sit in a recurring-use market, so each IVF cycle drives repeat demand. Global IVF use keeps expanding, and the large installed base in clinics helps CooperSurgical keep winning share. That makes this a Star in the BCG Matrix: high growth and a still-compounding position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat clinic demand supports sales\u003c\/li\u003e\n\u003cli\u003eInstalled base lowers switching risk\u003c\/li\u003e\n\u003cli\u003eGrowth still leaves room to gain share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooperVision’s Myopia and Toric Lenses Power Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars in The Cooper Companies, Inc. are led by CooperVision’s myopia, daily disposable, and toric lenses: MiSight 1 day targets a market where about 30% of people are affected and near 50% may be by 2050, while astigmatism affects about 30% too. In FY2025, these lines kept growth high as demand shifted to comfort and convenience.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiSight 1 day\u003c\/td\u003e\n\u003ctd\u003e30% affected; 50% by 2050\u003c\/td\u003e\n\u003ctd\u003eFDA-first mover\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiofinity Toric\u003c\/td\u003e\n\u003ctd\u003e30% astigmatism\u003c\/td\u003e\n\u003ctd\u003eLarge recurring demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix for The Cooper Companies maps its units into Stars, Cash Cows, Question Marks, and Dogs to guide invest\/hold\/divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for The Cooper Companies, Inc. that quickly spots stars, cash cows, and underperformers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for The Cooper Companies, Inc., making the analysis more credible and easier to trust, verify, and act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiofinity spherical monthly lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiofinity spherical monthly lenses are a mature core franchise inside CooperVision, and they keep producing steady repeat demand. In CooperCompanies' FY2025, net sales were about $4.0 billion, and this brand helps support that cash flow base. Growth is slower than newer lens types, but the monthly category is broad and dependable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePARAGARD copper IUD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePARAGARD is The Cooper Companies, Inc.’s long-settled U.S. copper IUD, approved for up to 10 years of use and backed by a durable non-hormonal niche. The U.S. IUD category is mature, so growth is limited, but PARAGARD still holds a stable spot in a high-value contraception market. That steady demand and low growth fit a classic cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvaira Vitality and other legacy lens lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvaira Vitality and CooperVision’s older replacement lens lines are classic cash cows: they serve a large installed base, so demand stays steady even when growth is slow. In fiscal 2025, The Cooper Companies reported about $4.0 billion in net sales, and these mature lenses need far less launch spending than new products. That makes them a reliable source of cash and margin support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProclear mature contact lens franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProclear is a mature CooperVision franchise with more than 20 years in market, so it behaves like a cash cow in The Cooper Companies, Inc. BCG Matrix. It serves a slower-growth reusable lens segment and leans on repeat buys from an installed base rather than new-user growth.\u003c\/p\u003e\n\u003cp\u003eThat makes it a harvest asset: steady cash, limited upside, and modest reinvestment needs versus newer silicone hydrogel or daily lens lines. In FY2025, CooperCompanies kept the franchise as part of a portfolio that generated about $4 billion in annual sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-life brand, repeat purchase model\u003c\/li\u003e\n\u003cli\u003eSlower growth, strong cash generation\u003c\/li\u003e\n\u003cli\u003eBest suited for harvest, not expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCooperSurgical office-based gynecology products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCooperSurgical office-based gynecology products, including uterine manipulators and retractors, sit in a mature, low-growth niche with steady procedure demand and sticky hospital relationships. They are cash cows because repeat use in routine gynecology helps support stable margin and cash flow across the surgical portfolio. The category’s role is less about rapid growth and more about dependable sales tied to recurring clinical workflows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady procedural demand\u003c\/li\u003e\n\u003cli\u003eMature, limited-growth category\u003c\/li\u003e\n\u003cli\u003eSticky hospital relationships\u003c\/li\u003e\n\u003cli\u003eSupports surgical cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooper Companies’ Cash Cows: Steady Revenue Engines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows in The Cooper Companies, Inc. are mature, repeat-buy businesses like Biofinity, Proclear, PARAGARD, and office-based gynecology tools. In FY2025, The Cooper Companies, Inc. reported about $4.0 billion in net sales, so these lines help fund the portfolio with steady cash, not fast growth. They fit a low-growth, high-cash BCG profile.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiofinity\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eRepeat demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePARAGARD\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003e10-year use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eThe Cooper Companies, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview you’re viewing is the exact The Cooper Companies, Inc. BCG Matrix document you’ll receive after purchase. No watered-down sample, no hidden pages—just the complete, professionally formatted file. Once purchased, it’s ready for immediate download and use. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume legacy surgical instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, low-volume legacy surgical instruments in The Cooper Companies, Inc. stayed in fragmented, low-growth niches, with small share and weak pricing power. They can add operating cost without much growth, so they fit the Dogs box. The key signal is a product line that consumes effort but rarely scales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall non-core closure devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSmall non-core closure devices fit the Dogs quadrant because closure accessories are commoditized, price-led, and crowded, so brand power is weak and growth is slow. In The Cooper Companies, Inc.'s fiscal 2025, CooperSurgical revenue was about $1.4 billion, but this niche is likely a low-share, low-growth slice of that base. That profile points more to break-even cash use than to expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional niche office products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperSurgical’s regional niche office products sit in the Dogs quadrant: narrow geography, low scale, and weak share make them hard to defend. Cooper Companies generated about $4 billion in fiscal 2025 sales, but these small office lines still face limited local demand and thin room for heavy investment. With low growth and low share, they fit classic value traps unless Cooper cuts cost or exits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOlder contact lens SKUs with declining demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder contact lens SKUs at The Cooper Companies, Inc. fit Dogs: daily disposables and premium silicone hydrogel lenses keep taking share, and legacy volume can fade as buyers trade up. In fiscal 2025, CooperVision still had to defend a mature portfolio while its growth leaned more on premium lines, so weak SKUs have little clear runway. Without a reset or exit plan, these aging lenses stay low-share, low-growth assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDaily disposables keep winning share.\u003c\/li\u003e\n\u003cli\u003ePremium silicone hydrogel lenses displace legacy SKUs.\u003c\/li\u003e\n\u003cli\u003eWeak growth path signals Dog status.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-strategic diagnostic accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-strategic diagnostic accessories fit the Dog box: they sit outside The Cooper Companies, Inc.'s fertility core and do not match the scale of CooperVision or CooperSurgical. In FY2025, Cooper Companies generated about $4.1 billion in revenue, but the main value still came from core reproductive and vision lines, not small add-ons.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share, low growth.\u003c\/li\u003e\n\u003cli\u003eWeak fit versus core franchises.\u003c\/li\u003e\n\u003cli\u003eLimited scale and pricing power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooper Companies’ Legacy Dogs: Small, Slow, and Hard to Defend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Cooper Companies'\" Dogs were small legacy lines with low share, weak pricing power, and little growth. They consumed operating effort but added limited scale, so they stayed value traps unless cut or exited. Cooper Companies reported about $4.1 billion in sales, but these niches were minor slices of that base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog area\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eLegacy surgical, closure, office, old lens SKUs\u003c\/td\u003e\n\u003ctd\u003eLow share, low growth, weak pricing power\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreimplantation genetic testing and reproductive genomics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCooperSurgical's genomics arm sits in a fast-growing IVF niche, but it is still less entrenched than Cooper's core contact lenses or PARAGARD. PGT adoption keeps rising as clinics bundle embryo testing with IVF workflows, so the unit can gain share if it wins more lab and clinic contracts. That makes it a BCG Question Mark: high growth, but not yet a dominant position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmbryo cryopreservation and lab automation expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmbryo cryopreservation and lab automation fit Question Marks because IVF labs are still standardizing workflows, even as demand keeps growing at roughly high-single-digit rates. CooperSurgical must keep funding equipment, software, and field sales to win share, since lab tools often need long validation cycles and heavy upfront capex. The category is attractive, but its competitive position is still being built.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyopia management outside core markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyopia care is growing fast outside CooperVision's core markets, with Asia-Pacific carrying the heaviest load: China alone had about 600 million people with myopia, and U.S. demand is still small versus that base. Cooper Companies reported about $3.9 billion in fiscal 2025 revenue, with CooperVision near $2.4 billion, so even modest share gains in Europe and Asia can move the needle. Early wins in orthokeratology and soft myopia-control lenses make these markets look like future Stars if rollout keeps widening.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePremium new daily disposable launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePremium new daily disposable launches can be a Question Mark for The Cooper Companies, Inc. because they can scale fast if eye-care practitioners adopt them, but launch share starts small against entrenched rivals. FY2025 sales still showed CooperVision depends on broad lens mix, so new premium SKUs need time, trials, and trade spend before they can turn into cash engines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast uptake needs practitioner buy-in\u003c\/li\u003e\n\u003cli\u003eEarly share usually stays modest\u003c\/li\u003e\n\u003cli\u003eHeavy promotion is still required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes the category high-growth but capital-hungry, which fits a classic BCG Question Mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital fertility workflow and AI-enabled lab tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital fertility workflows and AI lab tools are still early, but the prize is big: the U.S. saw 432,641 ART cycles and 95,860 live births in 2022, showing a large base for software-led gains. If CooperSurgical scales its workflow and data tools across clinics, this Question Mark can gain share fast and move toward Star status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly adoption, high upside\u003c\/li\u003e\n\u003cli\u003eClinic workflows are going digital\u003c\/li\u003e\n\u003cli\u003eScale can lift share and margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCooperSurgical's Fertility Bets Are Growing Question Marks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCooperSurgical's genomics, IVF lab tools, and digital fertility software are Question Marks: IVF demand is rising, but share is still building. With Cooper Companies at about $3.9 billion FY2025 revenue and CooperVision near $2.4 billion, these units can matter if they win more clinic contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eQuestion Mark\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eFY2025 base\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIVF genomics\u003c\/td\u003e\n\u003ctd\u003eHigh growth, low share\u003c\/td\u003e\n\u003ctd\u003eART demand up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab automation\u003c\/td\u003e\n\u003ctd\u003eCapex-heavy rollout\u003c\/td\u003e\n\u003ctd\u003eClinic adoption rising\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital fertility\u003c\/td\u003e\n\u003ctd\u003eEarly but scalable\u003c\/td\u003e\n\u003ctd\u003eU.S. 432,641 ART cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191828947209,"sku":"coo-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/coo-bcg-matrix.webp?v=1783678464","url":"https:\/\/dcfanalyst.com\/products\/coo-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}